about
More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.The genetic and molecular pathogenesis of myelodysplastic syndromes.Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right placeAplastic anemia: etiology, molecular pathogenesis and emerging conceptsPatterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapyManagement of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyCui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromesLeukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefitsHealthcare expenses for treatment of acute myeloid leukemiaHedgehog pathway inhibition as a therapeutic target in acute myeloid leukemiaAllogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerationsWhat is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?Getting personal with myelodysplastic syndromes: is now the right time?Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
P50
Q50052465-E93F9990-A087-4874-A353-4727AEAB5D86Q54979472-268D9D86-D884-406F-8DA7-FC8502BB0E68Q57163723-87C60A5A-2F25-4051-95EA-4FD1B7A51516Q57174293-38C61E86-B282-45CC-8A12-85B507306CE4Q89889199-3C568CDE-26C7-4971-BAB9-9117F4C347B7Q90053596-88E2E705-D2CF-4421-A182-C64303E0D2D2Q90391799-1B0A3058-E171-4E10-A5A6-9B4075688E7CQ91575479-1265A6C1-A162-4307-B673-B15E66A9C9D4Q92496111-B35201F1-50A3-496D-A93E-4292BB935C32Q92680778-4FD7791B-51CE-4B6E-B310-D7762416CE11Q92819658-597E738D-7CEB-41C6-9CEF-D644B9950DF2Q92876463-2B341D56-61BD-493B-9224-6B5EFAA659C5Q93050474-B3D59A5C-6A14-4D99-B533-29739C8EA261Q93247889-5B4AC2A4-F071-4B22-99F2-19F8FA4F26BDQ94499158-3E978E78-D015-44CC-88EA-4549610B3FC0
P50
description
researcher (ORCID 0000-0002-8542-2944)
@en
name
Amer M Zeidan
@en
type
label
Amer M Zeidan
@en
prefLabel
Amer M Zeidan
@en
P31
P496
0000-0002-8542-2944